HIMS supply chain intelligence for Hims & Hers Health, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BARCLAYS-BANK-PLC | BARCLAYS-BANK-PLC | 90% | the Company entered into privately negotiated capped call transactions with HSBC Bank USA, National Association, Barclays Bank PLC, BNP Paribas, Truist Bank and Morgan Stanley & Co. LLC |
| BNP-PARIBAS | BNP-PARIBAS | 90% | the Company entered into privately negotiated capped call transactions with HSBC Bank USA, National Association, Barclays Bank PLC, BNP Paribas, Truist Bank and Morgan Stanley & Co. LLC |
| HSBC-BANK-USA-NATIONAL-ASSOCIATION | HSBC-BANK-USA-NATIONAL-ASSOCIATION | 90% | the Company entered into privately negotiated capped call transactions with HSBC Bank USA, National Association, Barclays Bank PLC, BNP Paribas, Truist Bank and Morgan Stanley & Co. LLC |
| MORGAN-STANLEY-CO-LLC | MORGAN-STANLEY-CO-LLC | 90% | the Company entered into privately negotiated capped call transactions with HSBC Bank USA, National Association, Barclays Bank PLC, BNP Paribas, Truist Bank and Morgan Stanley & Co. LLC |
| SEAVIEW-ENTERPRISES-LLC-D-B-A-MEDISOURCERX | SEAVIEW-ENTERPRISES-LLC-D-B-A-MEDISOURCERX | 90% | In 2024, we acquired Seaview Enterprises, LLC (d/b/a MedisourceRx) (MedisourceRx), a licensed 503B compounding outsourcing facility, which compounds products primarily for Hims & Hers customers (our … |
| TRUIST-BANK | TRUIST-BANK | 90% | the Company entered into privately negotiated capped call transactions with HSBC Bank USA, National Association, Barclays Bank PLC, BNP Paribas, Truist Bank and Morgan Stanley & Co. LLC |
| XECARE-LLC | XECARE-LLC | 90% | In 2021, we completed our acquisition of YoDerm, Inc. (Apostrophe), allowing us to expand personalized dermatological offerings to our customers. Apostrophe Pharmacy LLC (Apostrophe Pharmacy, and tog… |
| SELLER | SELLER | 85% | Additionally, as part of the transaction, the Company entered into a transition services agreement with the Seller under which the Company will receive certain services and technical support during t… |
| C-S-BIO-CO | C-S-BIO-CO | 80% | Additionally, in February 2025, we acquired a peptide manufacturing facility and certain related assets from C S Bio, Co., which will allow us to expand our supply chain capabilities in the future (o… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PARTNER-PHARMACIES | PARTNER-PHARMACIES | 90% | The Company accounts for prescription product revenue from Partner Pharmacies as a principal in the arrangement with its customers. |
| ADDITIONALLY-APOSTROPHE-PHARMACY-LLC | ADDITIONALLY-APOSTROPHE-PHARMACY-LLC | 85% | health providers; collectively referred to as “Providers” or individually, a “Provider”) to provide consultation services. We determined that we are the primary beneficiary of the Affiliated Medical … |
| PLATFORM-PARTNERS | PLATFORM-PARTNERS | 85% | Further, to provide access to certain products, a substantial majority of which are prescription products, the Company has contracts with third-party platform partners ("Platform Partners"). |
| WHOLESALE-PARTNERS | WHOLESALE-PARTNERS | 75% | Additionally, in the United States, the Company offers a range of health and wellness products through wholesale partners, with such revenue not considered significant. |
| EHT-PHARMACY-LLC | EHT-PHARMACY-LLC | 62% | ine. We are the exclusive administrative services provider for the Affiliated Medical Groups, and the Affiliated Medical Groups provide services to patients exclusively through the Hims & Hers platfo… |
| HERS-UK-LIMITED | HERS-UK-LIMITED | 62% | gital-first, cloud-based business model has driven rapid adoption in the U.S. Additionally, our model has been developed to be scalable and applicable across new markets and languages. We expanded in… |
| HONEST-HEALTH-LIMITED | HONEST-HEALTH-LIMITED | 62% | ich were strategically priced to attract new customers. The decrease was partially offset by lower costs associated with medical consultation services as a percent of revenue as a result of improving… |
| SEAVIEW-ENTERPRISES-LLC | SEAVIEW-ENTERPRISES-LLC | 62% | opened an approximately 300,000 square foot facility in New Albany, Ohio. In 2021, this facility began housing a dedicated licensed mail order pharmacy, XeCare, LLC (or “XeCare”), that provides presc… |
| U-K-BASED-HONEST-HEALTH-LIMITED | U-K-BASED-HONEST-HEALTH-LIMITED | 62% | gital-first, cloud-based business model has driven rapid adoption in the U.S. Additionally, our model has been developed to be scalable and applicable across new markets and languages. We expanded in… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| HIMS-DEBT-10015 | Warrants outstanding: 61000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| HIMS-DEBT-10016 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| HIMS-DEBT | Debt stack $1.1B | 90% | Market cache reports total debt of $1.1B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| HIMS-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 445 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CANF | Can-Fite BioPharma Ltd. | 100.00 | 2 | |
| LLY | Eli Lilly and Company | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| ASND | Ascendis Pharma A/S | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| EVAX | Evaxion A/S | 100.00 | 2 | |
| IPHA | Innate Pharma S.A. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| JNJ | Johnson & Johnson | 100.00 | 2 | |
| NONOF | Novo Nordisk A/S | 100.00 | 2 | |
| NKTR | Nektar Therapeutics | 50.00 | 2 | |
| GYRE | Gyre Therapeutics, Inc. | 50.00 | 2 | |
| KRRO | Korro Bio, Inc. | 50.00 | 2 | |
| MDGL | Madrigal Pharmaceuticals, Inc. | 50.00 | 2 | |
| SNY | Sanofi | 50.00 | 2 | |
| SNYNF | Sanofi | 50.00 | 2 | |
| PRTA | Prothena Corporation plc | 50.00 | 2 | |
| RANI | Rani Therapeutics Holdings, Inc. | 50.00 | 2 | |
| IXHL | Incannex Healthcare Inc. | 50.00 | 2 | |
| LCTX | Lineage Cell Therapeutics, Inc. | 50.00 | 2 |